ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs MXN
16.99024
-0.30%
Brent Oil
81.295
0.00%
Bitcoin
67,678.33
0.29%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Sangamo Therapeutics Inc (SGMO)

  7. Sangamo Therapeutics Inc (SGMO) Noticias

SGMO Sangamo Therapeutics Inc

0.5364
-0.0088 (-1.61%)
31 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Sangamo Therapeutics Inc SGMO NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.0088 -1.61% 0.5364 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.54 0.5326 0.58 0.5644 0.5452
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
29/5/202416:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/5/202416:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/5/202416:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/5/202415:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/5/202415:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202415:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202415:01EDGAR2Form 8-K - Current report
09/5/202415:01BWSangamo Therapeutics Reports Recent Business Highlights and..
09/5/202407:05BWSangamo Therapeutics Presents Next-Generation Modular..
02/5/202415:15BWSangamo Therapeutics Announces First Quarter 2024 Conference..
22/4/202415:35BWSangamo Therapeutics to Present Neurology-Focused..
22/3/202407:05BWSangamo Therapeutics Announces Pricing of $24.0 Million..
13/3/202407:05BWSangamo Therapeutics Reports Recent Business Highlights and..
13/3/202407:01BWSangamo Therapeutics Announces Data From Novel Proprietary..
12/3/202417:30BWSangamo Therapeutics Announces Fourth Quarter and Full Year..
27/2/202416:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202416:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202416:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202416:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202416:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202407:05BWSangamo Therapeutics Announces U.S. FDA Alignment on..
06/2/202415:35EDGAR2Form 8-K - Current report
05/2/202417:01BWSangamo Therapeutics Announces Updated Phase 1/2 STAAR Study..
26/1/202410:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
24/1/202415:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202415:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202415:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202415:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202415:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202416:09EDGAR2Form 8-K - Current report
13/12/202306:55EDGAR2Form 8-K - Current report
28/11/202315:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202315:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202315:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202315:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202315:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202315:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202315:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/11/202315:02EDGAR2Form 8-K - Current report
01/11/202315:17EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202315:02EDGAR2Form 8-K - Current report
01/11/202315:01BWSangamo Therapeutics Announces Strategic Update and Reports..
25/10/202315:15BWSangamo Therapeutics Announces Third Quarter 2023 Conference..
24/10/202301:01BWSangamo Therapeutics to Present Pre-Clinical Data Showcasing..
20/9/202315:15BWSangamo Therapeutics to Present at the Jefferies Cell &..
29/8/202315:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202315:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202315:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202315:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202315:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

NASDAQ
SGMO
Sangamo Therapeutics
USOTC
TRRCF
Tribeca Res Corp Com (QB)
USOTC
TYABY
Turkiye IS Bankasi AS C (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados